Epidemiology Seminar
EPIDEMIOLOGY SEMINAR SERIES - Fall 2015
Jack Siemiatycki
Professor of Epidemiology, Guzzo-Cancer Research Society Chair in Environment and Cancer, UniversitĂ© de MontrĂ©al, School of Public Health, Adjunct Professor, EBOH, Ď㽶ĘÓƵ
How to provide epidemiologic support for a class action lawsuit against the tobacco industry
ALL ARE WELCOME
SYNOPSIS:
Lawsuits against the tobacco industry, if successful, have the potential to compensate victims of smoking and to diminish the capacity of the tobacco industry to continue to function with impunity. Up to now, the only successful legal actions against Big Tobacco have been those brought on behalf of states or provinces to recover national health care costs associated with tobacco diseases, and those brought on behalf of individual victims, in which financial damages were sought.
Class action lawsuits to recover damages on behalf of the huge numbers of victims have not previously been successful. The problem is that the tobacco industry has successfully argued that such a lawsuit requires a demonstration of “more likely than not” causation for each plaintiff. Depending on the jurisdiction, there may be many thousands or millions of incident cases annually, and it is impossible to bring them all into court individually to determine whether smoking was “more likely than not” a contributing cause of each case.
Fifteen years ago, class action suit was launched in Quebec on behalf of all lung cancer patients whose disease was caused by cigarette smoking. The plaintiffs’ lawyers asked me to estimate how many cases of cancer were caused by smoking. This sounds like the classic attributable fraction in epidemiology. But upon refinement, the question became one that has not previously been addressed in epidemiology: What proportion of lung cancer cases in Quebec, if they hypothetically could be individually evaluated, would satisfy the “more likely than not” criterion?
The novel methodology I developed is based on two stages. First I estimated the dose-response relationship between smoking and lung cancer, for which I use the pack-years as a measure of smoking. I define the amount of smoking that is required to induce a two-fold risk as the “critical amount” that makes it more likely than not that smoking contributed to the cancer. Depending on the model used and considering statistical variability, I estimated that the critical amount required to double the risk was somewhere between 5 and 12 pack-years of smoking.
Then I had to estimate what fraction of Quebec lung cancer patients had smoked more than the critical amount. I estimated this to be over 90%.
The Quebec trial, at which I testified and was cross-examined at length and criticized by a parade of defense witnesses, ended in 2014. The judge has made his judgement. He supported the plaintiffs. I will describe some aspects of the trial.
OBJECTIVES:
1) Explain and demonstrate a novel epidemiologic parameter that can be used in class action lawsuits.
2) Describe how epidemiologic research can feed into a legal framework.
3) Describe the outcome of a trial against the Canadian tobacco industry.
BIO:
Jack Siemiatycki has a PhD in epidemiology from Ď㽶ĘÓƵ and is currently Professor of epidemiology at l’UniversitĂ© de MontrĂ©al. He has held a Canada Research Chair and is currently the Guzzo-SRC Chair in Environment and Cancer, and is a fellow of the Canadian Academy of Health Sciences. He has served on over 150 national and international boards and expert advisory bodies for academic and government agencies in Canada, the US and Europe, such as the National Cancer Institute of Canada, Canadian Institutes of Health Research, National Cancer Institute (U.S.), Institut de recherche en santĂ© publique (France), INSERM (France), American College of Epidemiology, IARC and WHO. He was an associate editor of Amer J Epidemiology, and other journals, and he has chaired many grant review panels. Most of his research has been in the area of environmental and occupational etiology of cancer. He is known for having developed novel and influential design and exposure assessment methods in occupational etiology of cancer, and for results from a variety of case-control studies concerning a wide variety of possible environmental carcinogens. In the authoritative IARC Monograph program, his research results have been cited more often than those of any other epidemiology research team. Prof Siemiatycki has been an invited speaker at over 160 meetings or seminars throughout the world, including for President Clinton’s Cancer Panel, and as a Distinguished Lecturer at the U.S. National Cancer Institute. He has authored or co-authored over 270 peer-reviewed articles, chapters and scientific reports. He was the principal expert witness in the largest ever successful class action lawsuit against the tobacco industry.
Ěý
Ěý